Metabolic Health
Why Is Weight Loss So Hard? The Biology Behind the Struggle
Weight loss is hard because your body actively fights it. Hormones, metabolism, and the brain all work together to defen...
Ozempic (semaglutide) is not registered with DRAP (Drug Regulatory Authority of Pakistan) for the weight loss indication. For type 2 diabetes, some limited availability may exist through licensed import channels for specific physicians. For weight loss in people without diabetes, there is no official DRAP-registered pathway.
This does not mean Ozempic is completely unavailable — but understanding what "available" actually means in Pakistan matters for patient safety.
The Regulatory Situation
DRAP is Pakistan's national drug regulator, equivalent to the FDA in the US or MHRA in the UK. A drug must be registered with DRAP to be legally marketed, sold, or dispensed in Pakistan.
Semaglutide is not currently DRAP-registered in Pakistan for either the diabetes indication (Ozempic) or the obesity indication (Wegovy) under mainstream registration. Some specialist importers may have product available through specific regulatory pathways, but this is not the standard retail or pharmacy channel.
What "Available Through Informal Channels" Means
Despite the regulatory status, some product marketed as Ozempic does circulate in Pakistan through:
Grey market imports: Pharmaceutical traders import from countries where Ozempic is registered (UAE, India, UK, US). These products may be genuine, but they are imported outside official DRAP channels and sold without the regulatory oversight that official registration provides.
Online sellers and social media: Multiple Pakistani social media accounts and online sellers offer Ozempic. The authenticity, cold chain integrity, and regulatory status of these products cannot be verified by a buyer. Counterfeit pharmaceutical products are a real risk in unregulated supply chains.
Private physicians: Some physicians in major cities (Karachi, Lahore, Islamabad) source semaglutide through grey market channels for patients with type 2 diabetes, with less consistent availability for weight loss in non-diabetics.
The Risks of Informal Ozempic in Pakistan
Cold chain failure: Semaglutide pens must be refrigerated at 2 to 8°C before first use. Informal imports often cannot guarantee unbroken cold chain across international shipping, customs, and storage. Semaglutide exposed to temperatures outside the recommended range may lose potency or safety.
Counterfeit risk: Fake pharmaceutical products are prevalent in markets with limited supply chain regulation. A product in an Ozempic pen may not contain semaglutide at all, or may contain it at incorrect doses with impure formulation.
No regulatory recourse: If a product causes harm through substandard quality, there is no DRAP-regulated compensation or accountability framework for informally imported products.
No physician continuity: Without an official prescribing framework, patients often self-administer without appropriate screening, dose guidance, or monitoring.
The DRAP-Registered Alternative
METASLIM is a DRAP-registered GLP-1 sublingual weight loss supplement — the only GLP-1 pathway weight management option with full regulatory registration in Pakistan. It is:
- Available nationwide through cash on delivery
- Formulated at 2000 mcg/ml for sublingual administration
- Delivered through an 8-week physician-guided program
- Monitored by a panel of Pakistani physicians
- Produced under quality standards consistent with DRAP registration
For Pakistani patients who want GLP-1 pathway weight management without the authenticity risks, cold chain uncertainties, and regulatory grey area of informal Ozempic imports, METASLIM is the evidence-based starting point.